Published in Circ Arrhythm Electrophysiol on August 01, 2008
Genetics of congenital and drug-induced long QT syndromes: current evidence and future research perspectives. J Interv Card Electrophysiol (2013) 0.94
Genetics of long QT syndrome. Methodist Debakey Cardiovasc J (2014) 0.89
LQT1 mutations in KCNQ1 C-terminus assembly domain suppress IKs using different mechanisms. Cardiovasc Res (2014) 0.77
Genotyping has a minor role in selecting therapy for congenital long-QT syndromes at present. Circ Arrhythm Electrophysiol (2008) 0.76
Genetic testing for long QT syndrome and the category of cardiac ion channelopathies. PLoS Curr (2012) 0.75
Risk stratification in young patients with channelopathies. Indian Pacing Electrophysiol J (2010) 0.75
Empirical correlation of triggered activity and spatial and temporal re-entrant substrates with arrhythmogenicity in a murine model for Jervell and Lange-Nielsen syndrome. Pflugers Arch (2009) 0.75
[Genetic testing in hereditary arrythmia syndromes today and in the future]. Herzschrittmacherther Elektrophysiol (2012) 0.75
Genotype-phenotype correlation in the long-QT syndrome: gene-specific triggers for life-threatening arrhythmias. Circulation (2001) 7.47
Risk stratification in the long-QT syndrome. N Engl J Med (2003) 7.25
Effectiveness and limitations of beta-blocker therapy in congenital long-QT syndrome. Circulation (2000) 5.09
Long QT syndrome patients with mutations of the SCN5A and HERG genes have differential responses to Na+ channel blockade and to increases in heart rate. Implications for gene-specific therapy. Circulation (1995) 4.48
Cellular basis for the normal T wave and the electrocardiographic manifestations of the long-QT syndrome. Circulation (1998) 4.13
Clinical practice. Long-QT syndrome. N Engl J Med (2008) 4.05
The long QT syndrome. Prospective longitudinal study of 328 families. Circulation (1991) 3.99
ECG T-wave patterns in genetically distinct forms of the hereditary long QT syndrome. Circulation (1995) 3.79
Influence of genotype on the clinical course of the long-QT syndrome. International Long-QT Syndrome Registry Research Group. N Engl J Med (1998) 3.41
Association of long QT syndrome loci and cardiac events among patients treated with beta-blockers. JAMA (2004) 3.24
Implantable cardioverter defibrillator in high-risk long QT syndrome patients. J Cardiovasc Electrophysiol (2003) 3.05
Long QT syndrome in adults. J Am Coll Cardiol (2007) 2.93
Clinical aspects of type-1 long-QT syndrome by location, coding type, and biophysical function of mutations involving the KCNQ1 gene. Circulation (2007) 2.88
KCNH2-K897T is a genetic modifier of latent congenital long-QT syndrome. Circulation (2005) 2.78
Left cardiac sympathetic denervation in the management of high-risk patients affected by the long-QT syndrome. Circulation (2004) 2.63
Risk factors for aborted cardiac arrest and sudden cardiac death in children with the congenital long-QT syndrome. Circulation (2008) 2.40
Ranolazine shortens repolarization in patients with sustained inward sodium current due to type-3 long-QT syndrome. J Cardiovasc Electrophysiol (2008) 2.39
Multiple mechanisms of Na+ channel--linked long-QT syndrome. Circ Res (1996) 2.29
A new oral therapy for long QT syndrome: long-term oral potassium improves repolarization in patients with HERG mutations. J Am Coll Cardiol (2003) 2.28
Increased risk of arrhythmic events in long-QT syndrome with mutations in the pore region of the human ether-a-go-go-related gene potassium channel. Circulation (2002) 2.20
Risk of aborted cardiac arrest or sudden cardiac death during adolescence in the long-QT syndrome. JAMA (2006) 2.12
Dominant-negative KvLQT1 mutations underlie the LQT1 form of long QT syndrome. Circulation (1997) 2.02
Antagonism by ranolazine of the pro-arrhythmic effects of increasing late INa in guinea pig ventricular myocytes. J Cardiovasc Pharmacol (2004) 1.94
Location of mutation in the KCNQ1 and phenotypic presentation of long QT syndrome. J Cardiovasc Electrophysiol (2003) 1.91
Genetically defined therapy of inherited long-QT syndrome. Correction of abnormal repolarization by potassium. Circulation (1996) 1.86
Long QT syndrome-associated mutations in the Per-Arnt-Sim (PAS) domain of HERG potassium channels accelerate channel deactivation. J Biol Chem (1999) 1.82
Gating properties of SCN5A mutations and the response to mexiletine in long-QT syndrome type 3 patients. Circulation (2007) 1.82
Long-QT syndrome after age 40. Circulation (2008) 1.73
Long QT syndrome and pregnancy. J Am Coll Cardiol (2007) 1.71
Gene-specific differences in the circadian variation of ventricular repolarization in the long QT syndrome: a key to sudden death during sleep? Ital Heart J (2000) 1.59
The common long-QT syndrome mutation KCNQ1/A341V causes unusually severe clinical manifestations in patients with different ethnic backgrounds: toward a mutation-specific risk stratification. Circulation (2007) 1.58
Novel LQT-3 mutation affects Na+ channel activity through interactions between alpha- and beta1-subunits. Circ Res (1998) 1.56
Mutation site-specific differences in arrhythmic risk and sensitivity to sympathetic stimulation in the LQT1 form of congenital long QT syndrome: multicenter study in Japan. J Am Coll Cardiol (2004) 1.51
Phenotypic variability and unusual clinical severity of congenital long-QT syndrome in a founder population. Circulation (2005) 1.48
Effects of flecainide in patients with new SCN5A mutation: mutation-specific therapy for long-QT syndrome? Circulation (2000) 1.46
Arrhythmogenic mechanism of an LQT-3 mutation of the human heart Na(+) channel alpha-subunit: A computational analysis. Circulation (2000) 1.41
Normalization of ventricular repolarization with flecainide in long QT syndrome patients with SCN5A:DeltaKPQ mutation. Ann Noninvasive Electrocardiol (2001) 1.33
Comparison of clinical and genetic variables of cardiac events associated with loud noise versus swimming among subjects with the long QT syndrome. Am J Cardiol (1999) 1.25
Identification of the cyclic-nucleotide-binding domain as a conserved determinant of ion-channel cell-surface localization. J Cell Sci (2005) 1.25
Long QT syndrome: cellular basis and arrhythmia mechanism in LQT2. J Cardiovasc Electrophysiol (2000) 1.24
The long QT syndrome: therapeutic implications of a genetic diagnosis. Cardiovasc Res (2005) 1.14
Analysis of the cyclic nucleotide binding domain of the HERG potassium channel and interactions with KCNE2. J Biol Chem (2001) 1.06
Novel mutation in the Per-Arnt-Sim domain of KCNH2 causes a malignant form of long-QT syndrome. Circulation (2005) 1.00
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. Circulation (2004) 4.56
Long QT syndrome in adults. J Am Coll Cardiol (2007) 2.93
Clinical aspects of type-1 long-QT syndrome by location, coding type, and biophysical function of mutations involving the KCNQ1 gene. Circulation (2007) 2.88
Cardiac resynchronization therapy is more effective in women than in men: the MADIT-CRT (Multicenter Automatic Defibrillator Implantation Trial with Cardiac Resynchronization Therapy) trial. J Am Coll Cardiol (2011) 2.84
Genotype-phenotype aspects of type 2 long QT syndrome. J Am Coll Cardiol (2009) 2.65
Effectiveness of Cardiac Resynchronization Therapy by QRS Morphology in the Multicenter Automatic Defibrillator Implantation Trial-Cardiac Resynchronization Therapy (MADIT-CRT). Circulation (2011) 2.56
Predictors of super-response to cardiac resynchronization therapy and associated improvement in clinical outcome: the MADIT-CRT (multicenter automatic defibrillator implantation trial with cardiac resynchronization therapy) study. J Am Coll Cardiol (2012) 2.31
Left ventricular lead position and clinical outcome in the multicenter automatic defibrillator implantation trial-cardiac resynchronization therapy (MADIT-CRT) trial. Circulation (2011) 2.26
Risk of aborted cardiac arrest or sudden cardiac death during adolescence in the long-QT syndrome. JAMA (2006) 2.12
Long-term changes in serum cholesterol level does not influence the progression of coronary calcification. Int J Cardiol (2010) 1.99
Reverse remodeling and the risk of ventricular tachyarrhythmias in the MADIT-CRT (Multicenter Automatic Defibrillator Implantation Trial-Cardiac Resynchronization Therapy). J Am Coll Cardiol (2011) 1.95
Mutations in cytoplasmic loops of the KCNQ1 channel and the risk of life-threatening events: implications for mutation-specific response to β-blocker therapy in type 1 long-QT syndrome. Circulation (2012) 1.89
Clinical implications for patients with long QT syndrome who experience a cardiac event during infancy. J Am Coll Cardiol (2009) 1.81
The influence of left ventricular ejection fraction on the effectiveness of cardiac resynchronization therapy: MADIT-CRT (Multicenter Automatic Defibrillator Implantation Trial With Cardiac Resynchronization Therapy). J Am Coll Cardiol (2013) 1.79
Lipid-modifying therapies and risk of pancreatitis: a meta-analysis. JAMA (2012) 1.71
Long QT syndrome and pregnancy. J Am Coll Cardiol (2007) 1.71
Long QT Syndrome. Curr Probl Cardiol (2008) 1.70
Left atrial contractile function following a successful modified Maze procedure at surgery and the risk for subsequent thromboembolic stroke. J Am Coll Cardiol (2011) 1.62
Serum uric acid for risk stratification of patients with coronary artery disease. Cardiology (2009) 1.61
Risk factors for recurrent syncope and subsequent fatal or near-fatal events in children and adolescents with long QT syndrome. J Am Coll Cardiol (2011) 1.59
Dyssynchrony and the risk of ventricular arrhythmias. JACC Cardiovasc Imaging (2013) 1.56
Obesity as a risk factor for sustained ventricular tachyarrhythmias in MADIT II patients. J Cardiovasc Electrophysiol (2007) 1.55
Mutation and gender-specific risk in type 2 long QT syndrome: implications for risk stratification for life-threatening cardiac events in patients with long QT syndrome. Heart Rhythm (2011) 1.54
In silico cardiac risk assessment in patients with long QT syndrome: type 1: clinical predictability of cardiac models. J Am Coll Cardiol (2012) 1.53
Risk stratification for implantable cardioverter defibrillator therapy: the role of the wearable cardioverter-defibrillator. Eur Heart J (2013) 1.52
Risk factors for recurrent heart failure events in the Multicenter Automatic Defibrillator Implantation Trial II (MADIT-II). J Cardiovasc Electrophysiol (2010) 1.52
Atrioventricular delay programming and the benefit of cardiac resynchronization therapy in MADIT-CRT. Heart Rhythm (2013) 1.52
Combined assessment of sex- and mutation-specific information for risk stratification in type 1 long QT syndrome. Heart Rhythm (2012) 1.47
Long-term implications of cumulative right ventricular pacing among patients with an implantable cardioverter-defibrillator. Heart Rhythm (2010) 1.47
Prognostic implications of mutation-specific QTc standard deviation in congenital long QT syndrome. Heart Rhythm (2013) 1.46
Predictors and course of high-degree atrioventricular block after transcatheter aortic valve implantation using the CoreValve Revalving System. Am J Cardiol (2011) 1.45
Peroxisome proliferator-activated receptor ligand bezafibrate for prevention of type 2 diabetes mellitus in patients with coronary artery disease. Circulation (2004) 1.42
Risk of recurrent cardiac events after onset of menopause in women with congenital long-QT syndrome types 1 and 2. Circulation (2011) 1.41
Functional response to cardiac resynchronization therapy in patients with renal dysfunction and subsequent long-term mortality. J Cardiovasc Electrophysiol (2014) 1.41
Risk of syncope in family members who are genotype-negative for a family-associated long-QT syndrome mutation. Circ Cardiovasc Genet (2011) 1.40
Timing of coronary angiography and outcome in patients with non-ST elevation acute coronary syndromes and kidney disease: real-world data from the acute coronary syndromes Israeli survey. Cardiology (2011) 1.40
Predictors of high-risk angiographic findings in patients with non-ST-segment elevation acute coronary syndrome. Catheter Cardiovasc Interv (2013) 1.39
Response to preventive cardiac resynchronization therapy in patients with ischaemic and nonischaemic cardiomyopathy in MADIT-CRT. Eur Heart J (2010) 1.33
Applicability of a risk score for prediction of the long-term (8-year) benefit of the implantable cardioverter-defibrillator. J Am Coll Cardiol (2012) 1.23
Prognostic significance of fragmented QRS complex for predicting the risk of recurrent cardiac events in patients with Q-wave myocardial infarction. Am J Cardiol (2007) 1.21
Risk of mortality for ventricular arrhythmia in ambulatory LVAD patients. J Cardiovasc Electrophysiol (2011) 1.10
Predictors of long-term mortality in Multicenter Automatic Defibrillator Implantation Trial II (MADIT II) patients with implantable cardioverter-defibrillators. Heart Rhythm (2008) 1.10
Risk of fatal arrhythmic events in long QT syndrome patients after syncope. J Am Coll Cardiol (2010) 1.06
Dyssynchrony, contractile function, and response to cardiac resynchronization therapy. Circ Heart Fail (2011) 1.05
Effectiveness of the implantable cardioverter defibrillator in blacks versus whites (from MADIT-II). Am J Cardiol (2006) 1.01
Time-dependent benefit of preventive cardiac resynchronization therapy after myocardial infarction. Eur Heart J (2010) 1.00
Long QT syndrome in patients over 40 years of age: increased risk for LQTS-related cardiac events in patients with coronary disease. Ann Noninvasive Electrocardiol (2008) 0.98
Statin use and reduced cancer-related mortality. N Engl J Med (2013) 0.94
Trigger-specific risk factors and response to therapy in long QT syndrome type 2. Heart Rhythm (2010) 0.94
Improved outcome with preventive cardiac resynchronization therapy in the elderly: a MADIT-CRT substudy. J Cardiovasc Electrophysiol (2011) 0.94
Risk of cardiac events in patients with asthma and long-QT syndrome treated with beta(2) agonists. Am J Cardiol (2008) 0.93
Cardiovascular events in patients received combined fibrate/statin treatment versus statin monotherapy: Acute Coronary Syndrome Israeli Surveys data. PLoS One (2012) 0.93
Cardiac resynchronization therapy reduces left atrial volume and the risk of atrial tachyarrhythmias in MADIT-CRT (Multicenter Automatic Defibrillator Implantation Trial with Cardiac Resynchronization Therapy). J Am Coll Cardiol (2011) 0.92
Relation of bundle branch block to long-term (four-year) mortality in hospitalized patients with systolic heart failure. Am J Cardiol (2010) 0.92
Relationship between improvement in left ventricular dyssynchrony and contractile function and clinical outcome with cardiac resynchronization therapy: the MADIT-CRT trial. Eur Heart J (2011) 0.92
Risk of life-threatening cardiac events among patients with long QT syndrome and multiple mutations. Heart Rhythm (2012) 0.91
Usefulness of combining serum uric acid and C-reactive protein for risk stratification of patients with coronary artery disease (Bezafibrate Infarction Prevention [BIP] study). Am J Cardiol (2009) 0.91
Use of mutant-specific ion channel characteristics for risk stratification of long QT syndrome patients. Sci Transl Med (2011) 0.90
Risk factors for sudden cardiac death in patients with chronic renal insufficiency and left ventricular dysfunction. Am J Nephrol (2007) 0.89
Relation of body mass index to sudden cardiac death and the benefit of implantable cardioverter-defibrillator in patients with left ventricular dysfunction after healing of myocardial infarction. Am J Cardiol (2010) 0.88
Predictors of long-term (4-year) mortality in elderly and young patients with acute heart failure. Eur J Heart Fail (2010) 0.87
Wearable defibrillator in congenital structural heart disease and inherited arrhythmias. Am J Cardiol (2011) 0.85
Mutations in conserved amino acids in the KCNQ1 channel and risk of cardiac events in type-1 long-QT syndrome. J Cardiovasc Electrophysiol (2009) 0.85
Polymorphisms in the paraoxonase and endothelial nitric oxide synthase genes and the risk of early-onset myocardial infarction. Am J Cardiol (2007) 0.85
Association of elevated homocysteine levels with a higher risk of recurrent coronary events and mortality in patients with acute myocardial infarction. Arch Intern Med (2003) 0.85
Serologic testing for celiac disease in young adults--a cost-effect analysis. Dig Dis Sci (2005) 0.84
Long QT syndrome in African-Americans. Ann Noninvasive Electrocardiol (2010) 0.84
Genotype-specific risk stratification and management of patients with long QT syndrome. Ann Noninvasive Electrocardiol (2013) 0.83
Sex-related differences in patients' responses to heart failure therapy. Nat Rev Cardiol (2012) 0.83
Implantable cardioverter defibrillator efficacy and chronic kidney disease: competing risks of arrhythmic and nonarrhythmic mortality. J Cardiovasc Electrophysiol (2008) 0.82
Effects of a vildagliptin/metformin combination on markers of atherosclerosis, thrombosis, and inflammation in diabetic patients with coronary artery disease. Cardiovasc Diabetol (2012) 0.82
Right precordial lead (V4R) ST-segment elevation is associated with worse prognosis in patients with acute anterior myocardial infarction. J Am Coll Cardiol (2011) 0.82
The downside of right ventricular apical pacing. Indian Pacing Electrophysiol J (2012) 0.82
Brain natriuretic peptide and cardiac resynchronization therapy in patients with mildly symptomatic heart failure. Circ Heart Fail (2013) 0.82
Effect of mildly attenuated heart rate response during treadmill exercise testing on cardiovascular outcome in healthy men and women. Am J Cardiol (2013) 0.81
Thrombospondin-4 polymorphism (A387P) predicts cardiovascular risk in postinfarction patients with high HDL cholesterol and C-reactive protein levels. Thromb Haemost (2011) 0.81
Temporal Trends and Outcomes Associated with Major Bleeding in Acute Coronary Syndromes: A Decade-Long Perspective from the Acute Coronary Syndrome Israeli Surveys 2000-2010. Cardiology (2015) 0.81
Does the lipid-lowering peroxisome proliferator-activated receptors ligand bezafibrate prevent colon cancer in patients with coronary artery disease? Cardiovasc Diabetol (2008) 0.81
Mutation-specific risk in two genetic forms of type 3 long QT syndrome. Am J Cardiol (2010) 0.80
Real-World Use of Novel P2Y12 Inhibitors in Patients with Acute Myocardial Infarction: A Treatment Paradox. Cardiology (2016) 0.80
Time dependence of life-threatening ventricular tachyarrhythmias after coronary revascularization in MADIT-CRT. Heart Rhythm (2010) 0.80
Differences in heart rate profile during exercise among subjects with subclinical thyroid disease. Thyroid (2013) 0.79
Predictors and outcome of sustained improvement in left ventricular function in dilated cardiomyopathy. Clin Cardiol (2014) 0.79
Sitagliptin pretreatment in diabetes patients presenting with acute coronary syndrome: results from the Acute Coronary Syndrome Israeli Survey (ACSIS). Cardiovasc Diabetol (2013) 0.79
Survival with cardiac-resynchronization therapy. N Engl J Med (2014) 0.79
Response of right ventricular size to treatment with cardiac resynchronization therapy and the risk of ventricular tachyarrhythmias in MADIT-CRT. Heart Rhythm (2013) 0.79
Left ventricular lead location and the risk of ventricular arrhythmias in the MADIT-CRT trial. Eur Heart J (2012) 0.79
Effect of defibrillation threshold testing on heart failure hospitalization or death in the Multicenter Automatic Defibrillator Implantation Trial-Cardiac Resynchronization Therapy (MADIT-CRT). Heart Rhythm (2012) 0.79
Prevention of sudden cardiac death: need for a plaque stabilizer. Am Heart J (2010) 0.79
Left ventricular pacing threshold and outcome in MADIT-CRT. J Cardiovasc Electrophysiol (2014) 0.78
Effect of cardiac resynchronization therapy on the risk of first and recurrent ventricular tachyarrhythmic events in MADIT-CRT. J Am Coll Cardiol (2012) 0.78
Influenza vaccine and survival in acute heart failure. Eur J Heart Fail (2013) 0.78
Genotype-specific QT correction for heart rate and the risk of life-threatening cardiac events in adolescents with congenital long-QT syndrome. Heart Rhythm (2011) 0.78
Ion channel mechanisms related to sudden cardiac death in phenotype-negative long-QT syndrome genotype-phenotype correlations of the KCNQ1(S349W) mutation. J Cardiovasc Electrophysiol (2011) 0.78
Right ventricular function, pulmonary pressure estimation, and clinical outcomes in cardiac resynchronization therapy. Circ Heart Fail (2013) 0.78
Genetics of sudden cardiac death. Curr Cardiol Rep (2011) 0.78
Left atrial volume and the benefit of cardiac resynchronization therapy in the MADIT-CRT trial. Circ Heart Fail (2013) 0.77
Clinical course and outcome of patients enrolled in US and non-US centres in MADIT-CRT. Eur Heart J (2011) 0.77
Predictors and outcomes associated with radial versus femoral access for intervention in patients with acute coronary syndrome in a real-world setting: results from the Acute Coronary Syndrome Israeli Survey (ACSIS) 2010. J Invasive Cardiol (2014) 0.77
Phenotypic variability in Caucasian and Japanese patients with matched LQT1 mutations. Ann Noninvasive Electrocardiol (2008) 0.77